Oral Abstracts PAGE 2008 Meeting Marseille, France
Total Page:16
File Type:pdf, Size:1020Kb
Poster abstracts PAGE 2008 meeting Marseille, France Poster: Applications- Anti-infectives................................................................................................ 8 caroline BAZZOLI Population pharmacokinetics of AZT and its active metabolite AZT-TP in HIV patients: joint modelling and design optimisation ................................................ 8 helena colom Population pharmacokinetics of Ganciclovir following Valganciclovir in solid organ transplant recipients infected by cytomegalovirus...................................................... 10 ANNE DUBOIS Population analysis of plasma and intracellular pharmacokinetics of indinavir in HIV-1 infected patients with a stable antiretroviral therapy ...................................... 11 Monika Frank Nevirapine - Population pharmacokinetic model building and simulation for mothers and newborns............................................................................................ 13 María José García Sánchez Population Pharmacokinetics of Efavirenz in HIV- infected patients: Pharmacogenetic analysis.................................................................................. 14 Sylvain Goutelle A Population Pharmacokinetic Study of Plasma and Intrapulmonary Concentrations of Rifampin........................................................................................................... 15 Sylvain Goutelle Influence of Rifampin Pharmacokinetic Variability on Antibacterial Effect and Prevention of Resistance in Pulmonary Tuberculosis: a Simulation Study ................. 17 FLORA MUSUAMBA-TSHINANU Simultaneous Therapeutic Drug Monitoring Of Amikacin And Beta-Lactams In Intensive Care Unit Patients With Severe Sepsis Or Septic Shock Without Beta-Lactam Serum Concentration Monitoring......................................... 19 PARTHA NANDY Relationship Between a PK/PD Parameter and Therapeutic Response of Ceftobiprole in Patients with Complicate Skin and Skin Structure Infection ......................................................................................................................................... 20 Michael Neely Population Kinetics and Dynamics of Lopinavir in HIV-Infected Children.......................................................................................................................................... 21 Elisabet Nielsen Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates: Modelling and Simulation Based on Data from a Prospective Study........................... 23 Daniel Röshammar Population Pharmacokinetics of Efavirenz and MDR-1, CY2B6, and CYP3A5 Polymorphisms ........................................................................................................ 25 Catherine Mary Turner Sherwin Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates........................................................................ 26 Nicolas Simon Population Pharmacokinetics of Atazanavir in HIV-infected Patients.................. 28 Joel Tarning Population pharmacokinetics of lumefantrine in pregnant women treated with co-artemether for uncomplicated falciparum malaria............................................................ 29 Jan-Stefan van der Walt Population pharmacokinetic models for lamivudine and nevirapine to assess drug concentrations obtained during therapeutic drug monitoring ............... 31 Wei ZHAO Population Pharmacokinetics of Ganciclovir Following Oral Administration of its Prodrug Valganciclovir in Pediatric Renal Transplant Patients .................. 32 Poster: Applications- Biologicals/vaccines..................................................................................... 34 Daren Austin Use of mechanistic models to estimate target antigen load for monoclonal antibodies ................................................................................................................... 34 Brigitte Lacroix Exposure-Response Modeling of the ACR20 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. ..................................................................... 35 Brigitte Lacroix Exposure-response analysis of certolizumab pegol in Crohn’s disease population....................................................................................................................................... 36 Micha Levi Relationship Between Serum Concentration of the Interleukin-6 Receptor Inhibitor, Tocilizumab (TCZ), and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis ..................................................................................................................... 37 Etienne Pigeolet Granulocyte Colony Stimulating Factor Pharmacokinetics After Single and Repeated Administration of Several Doses. ................................................................ 38 1 David Ternant Development of anti-infliximab antibodies increases infliximab clearance in inflammatory bowel diseases..................................................................................... 39 Justin Wilkins Bioequivalence, bootstrapping and case-deletion diagnostics in a biologic: a model-based analysis of the effect of formulation differences in a monoclonal antibody...................................................................................................................... 40 Poster: Applications- CNS............................................................................................................... 42 Aliénor Bergès Using VT (total volume of distribution from PET) in estimating the PK-Receptor Occupancy relationship in the absence of reference regions. .................................. 42 Chao Chen Population modeling of the relationship between ropinirole systemic exposure and efficacy in Parkinson’s disease................................................................................ 44 Rik de Greef Modeling and Simulation to Integrate Efficacy and Safety Data Following Full Development: a Case Study in Schizophrenia and Bipolar Disorder ................... 45 Geraldine Ferron PK and PK/PD modeling of CB1 blocker antagonism of THC induced CNS and Heart Rate effect ............................................................................................... 46 Sophie Gisbert Analysing Raw Count data from an In Vitro Target Occupancy Assay to Select Doses for Human Safety/Tolerability Trial..................................................................... 47 Dymphy Huntjens PK/PD modeling of apomorphine-induced behaviour in macaques ................ 48 Brigitte Lacroix Population Pharmacokinetics of Brivaracetam in Patients with Partial Epilepsy.......................................................................................................................................... 49 Bart Laurijssens Model-Based Analysis of a Longitudinal Binary Response as the Primary Analysis for a Phase II Study in Migraine Prophylaxis. .................................................. 50 Otilia Lillin-de Vries A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers. ................................. 52 IGOR LOCATELLI Population Pharmacokinetics of Risperidone in Patients with Acute Schizophrenia ...................................................................................................................... 53 Guangli Ma Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin.................................................................................................... 55 Sarah McLeay Scaling propofol doses for the obese: is lean body weight the answer?................ 56 Raymond Miller Exposure-Response Analysis of Longitudinal Adverse Event Data................... 58 Gianluca Nucci A sparse sample PK & PKPD approach to estimate the time course of antipsychotic-induced D2 occupancy ............................................................................................ 59 Elba Romero Extended Link Model to Describe the Impact of Chronic Antiepileptic Therapy on the Effects of Neuromuscular Blocking Agents. ........................................................ 61 Monica Simeoni Modelling beta amyloid system: sensitivity analysis at steady state and in dynamic conditions. ............................................................................................................ 62 Armel Stockis Levetiracetam exposure-response analysis in children with partial onset seizures........................................................................................................................................... 63 Katarina Vucicevic Estimation of Relative Bioavailability of Controlled-Release Carbamazepine Tablets Based on Routine TDM Data .................................................................. 64 Stefano Zamuner Mixed Effects Markov Models for Modelling Sleep in Insomniac Patients Treated with Placebo in a 28 Days Trial: Emphasis on the Break Points Selection......................................................................................................................................... 65 Poster: Applications- Coagulation.................................................................................................. 67 Xavier Delavenne Assessment of pharmacokinetic variability of fondaparinux in 809 patients treated after major orthopedic surgery: the POP-A-RIX study ........................................ 67